As filed with the Securities and Exchange Commission
on January 20, 2021
Registration
No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
Form S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
____________________
CNS Pharmaceuticals, Inc.
(Exact name of registrant as specified in its Charter)
Nevada
(State
or other jurisdiction of incorporation)
|
82-2318545
(I.R.S.
Employer Identification No.)
|
2100 West Loop South, Suite 900
Houston, Texas 77027
(800) 946-9185
(Address of principal executive offices, including
zip code, and telephone number, including area code)
____________________
John Climaco
Chief Executive Officer
2100 West Loop South, Suite 900
Houston, Texas 77027
(800) 946-9185
(Name, address, including zip code, and telephone
number, including area code, of agent for service of process)
____________________
Copies to:
Cavas S. Pavri
Schiff Hardin LLP
100 N. 18th Street, Suite 300
Philadelphia, PA 19103
Telephone: (202) 724-6847
Facsimile: (202) 778-6460
Approximate date of commencement of proposed
sale to the public: From time to time after the effective date of this registration statement.
If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. o
If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than
securities offered only in connection with dividend or interest reinvestment plans, please check the following box. ý
If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, as amended, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. o
If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, as amended, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. o
If this Form is a registration statement pursuant
to General Instruction 1.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. o
If this Form is a post-effective amendment to
a registration statement filed pursuant to General Instruction 1.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. o
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging
growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
o
|
|
Accelerated filer
|
o
|
|
|
|
|
|
|
|
Non-accelerated filer
|
ý
|
|
Smaller reporting company
|
ý
|
|
|
|
|
Emerging growth company
|
ý
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.
____________________
CALCULATION OF REGISTRATION FEE
Title of each class of
securities to be registered
|
Amount to be registered (1)
|
Proposed
maximum
offering price per share (2)
|
Proposed
maximum
aggregate
offering price (2)
|
Amount of
registration fee
|
Common Stock, par value $0.001 per share
|
24,815,791
|
$0.74
|
$18,363,685.34
|
$1,702.31
|
(1)
|
Represents (i) 9,489,474 shares of common stock, par value $0.001 per share, of the registrant (“Common Stock”) in a private placement transaction, (ii) 2,615,790 shares of Common Stock that are issuable upon the exercise of a certain pre-funded warrant that was acquired by a selling stockholder in a private placement transaction, (iii) 12,105,264 shares of Common Stock that are issuable upon the exercise of certain warrants that were acquired by the selling stockholders in a private placement transaction and (iv) 605,263 shares of Common Stock that are issuable upon exercise of certain warrants issued to the placement agent pursuant to an engagement letter in connection with such private placement transaction, each of which may be sold by the selling stockholders named in this registration statement. Pursuant to Rule 416 of the Securities Act of 1933, as amended, this registration statement also covers such an indeterminate amount of shares of Common Stock as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.
|
|
|
(2)
|
Calculated pursuant to Rule 457(c), solely for the purpose of computing the amount of the registration fee, on the basis of the average of the high and low prices of the registrant’s Common Stock quoted on The Nasdaq Capital Market on January 14, 2022.
|
The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant
shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and
Exchange Commission, acting pursuant to said Section 8(a), may determine.
The information in
this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an
offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to Completion,
dated January 20, 2022
PROSPECTUS
CNS Pharmaceuticals, Inc.
24,815,791 Shares of
Common Stock
____________________
Pursuant to this prospectus,
the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 24,815,791
shares of our common stock.
Of the foregoing, 24,210,528
shares of common stock offered for resale hereby were acquired by certain Selling Stockholders in a private placement transaction pursuant
to a securities purchase agreement by and among us and the Selling Stockholders, dated January 5, 2022 (the “Purchase Agreement”),
of which (i) 9,489,474 shares are outstanding and held by the Selling Stockholders, (ii) 2,615,790 shares are issuable upon the exercise
of pre-funded warrants held by the Selling Stockholders, and (iii) 12,105,264 shares are issuable upon the exercise of additional warrants.
In addition, 605,263 shares of common stock are issuable upon the exercise of warrants issued to our placement agent in the private placement,
H.C. Wainwright & Co., LLC, in connection with the Purchase Agreement.
We will not receive any
of the proceeds from the sale by the Selling Stockholders of the common stock. Upon any exercise of the warrants by payment of cash, however,
we will receive the exercise price of the warrants. We intend to use those proceeds, if any, for general corporate purposes.
The Selling Stockholders
may sell or otherwise dispose of the common stock covered by this prospectus in a number of different ways and at varying prices. We provide
more information about how the Selling Stockholders may sell or otherwise dispose of the common stock covered by this prospectus in the
section entitled “Plan of Distribution” on page 13. Discounts, concessions, commissions and similar selling expenses attributable
to the sale of common stock covered by this prospectus will be borne by the Selling Stockholders. We will pay all expenses (other than
discounts, concessions, commissions and similar selling expenses) relating to the registration of the common stock with the Securities
and Exchange Commission, or SEC.
Our common stock is listed
on The Nasdaq Capital Market under the symbol “CNSP.” On January 19, 2022, the last reported sale price for our common stock
was $0.747 per share.
Investing in our
securities involves risks. See “Risk Factors” beginning on page 5 and “Item 1A—Risk
Factors” of our most recent report on Form 10-K or 10-Q which is incorporated by reference in this
prospectus before you invest in our securities.
Neither the SEC nor
any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is
not permitted.
The date of this prospectus
is __________, 2022.
TABLE OF CONTENTS
ABOUT
THIS PROSPECTUS
This prospectus is part
of the registration statement that we filed with the Securities and Exchange Commission (the “SEC”) pursuant to which the
selling stockholders named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered
by this prospectus. As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information
not contained in this prospectus.
This prospectus and the
documents incorporated by reference into this prospectus include important information about us, the securities being offered and other
information you should know before investing in our securities. You should not assume that the information contained in this prospectus
is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated
by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered
or shares of common stock are sold or otherwise disposed of on a later date. It is important for you to read and consider all information
contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You should
also read and consider the information in the documents to which we have referred you under “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference” in this prospectus.
You should rely only
on this prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus. We have not, and the
selling stockholders have not, authorized anyone to give any information or to make any representation to you other than those contained
or incorporated by reference in this prospectus. If anyone provides you with different or inconsistent information, you should not rely
on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any
person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
We further note that
the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated
by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you.
Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs.
Unless otherwise
indicated, information contained or incorporated by reference in this prospectus concerning our industry, including our general
expectations and market opportunity, is based on information from our own management estimates and research, as well as from
industry and general publications and research, surveys and studies conducted by third parties. Management estimates are derived
from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we
believe to be reasonable. In addition, assumptions and estimates of our and our industry’s future performance are necessarily
uncertain due to a variety of factors, including those described in “Risk Factors” beginning on
page 5 of this prospectus. These and other factors could cause our future performance to differ materially from our assumptions and
estimates.
PROSPECTUS SUMMARY
This
summary highlights selected information from this prospectus and the documents incorporated herein by reference and does not contain
all of the information that you need to consider in making your investment decision. You should carefully read the entire
prospectus, including the risks of investing in our securities discussed under “Risk Factors”
beginning on page 5 of this prospectus, the information incorporated herein by reference, including our financial statements, and
the exhibits to the registration statement of which this prospectus is a part. All references in this prospectus to
“we,” “us,” “our,” “CNS,” the “Company” and similar designations refer
to CNS Pharmaceuticals, Inc., unless otherwise indicated or as the context otherwise requires.
Our Company
We are a clinical pharmaceutical
company organized as a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of
brain and central nervous system tumors, based on intellectual property that we license under license agreements with Houston Pharmaceuticals,
Inc. (“HPI”) and The University of Texas M.D. Anderson Cancer Center (“UTMDACC”) and own pursuant to a collaboration
and asset purchase agreement with Reata Pharmaceuticals, Inc. (“Reata”).
We believe our lead drug candidate,
Berubicin, if approved by the FDA, may be a significant discovery in the treatment of glioblastoma. Glioblastoma are tumors that arise
from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. These tumors are usually highly malignant (cancerous)
because the cells reproduce quickly, and they are supported by a large network of blood vessels. Berubicin is an anthracycline, which
is a class of drugs that are among the most powerful chemotherapy drugs known. Based on limited clinical data, we believe Berubicin is
the first anthracycline that appears to have crossed the blood brain barrier and target brain cancer cells. While our current focus is
solely on the development of Berubicin, we are also in the process of attempting to secure intellectual property rights in additional
compounds that may be developed into drugs to treat cancers.
Berubicin was discovered by
our founder, Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. Through a series
of transactions, Berubicin was initially licensed to Reata. Reata conducted a Phase I clinical trial on Berubicin but subsequently allowed
their IND with the FDA to lapse for strategic reasons. This required us to obtain a new IND for Berubicin before beginning further clinical
trials. On December 17, 2020, we announced that our IND application with the FDA for Berubicin for the treatment of Glioblastoma Multiforme
was in effect. We initiated our trial during the third quarter of 2021 to investigate the efficacy of Berubicin in adults with Glioblastoma
Multiforme who have failed first-line therapy. Recent correspondence between us and the FDA resulted in modifications to our previously
disclosed trial design, including designating overall survival (OS) as the primary endpoint of the study. OS is a rigorous endpoint that
the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to
a randomized control arm.
The Phase II trial currently
being conducted, which was open for enrollment during the second quarter of 2021 and treated the first patient during the third quarter
of 2021, will evaluate the efficacy of Berubicin in patients with Glioblastoma Multiforme who have failed primary treatment for their
disease, and results will be compared to the current standard of care, with 2 to 1 randomization of the 243 patients to Berubicin or Lomustine.
Subjects receiving Berubicin will be administered a 2-hour IV infusion of 7.5 mg/m2 berubicin hydrochloride daily for three consecutive
days followed by 18 days off (21-day cycle). Lomustine is administered orally. The trial will include an interim analysis that will evaluate
the comparative effectiveness of these treatments. Even if Berubicin is approved, there is no assurance that patients will choose an infusion
treatment, as compared to the current standard of care, which requires oral administration.
We do not have manufacturing
facilities and all manufacturing activities are contracted out to third parties. Additionally, we do not have a sales organization.
On November 21, 2017, we entered
into a Collaboration and Asset Purchase Agreement with Reata (the “Reata Agreement”). Pursuant to the Reata Agreement we purchased
all of Reata’s intellectual property and development data regarding Berubicin, including all trade secrets, knowhow, confidential
information and other intellectual property rights, which we refer to as the Reata Data.
On December 28, 2017, we obtained
the rights to a worldwide, exclusive royalty-bearing, license to the chemical compound commonly known as Berubicin from HPI in an agreement
we refer to as the HPI License. HPI is affiliated with Dr. Priebe, our founder and largest shareholder. Under the HPI License we obtained
the exclusive right to develop certain chemical compounds for use in the treatment of cancer anywhere in the world. In the HPI License
we agreed to pay HPI: (i) development fees of $750,000 over a three-year period beginning November 2019; (ii) a 2% royalty on net sales;
(iii) a $50,000 per year license fee; (iv) milestone payments of $100,000 upon the commencement of a Phase II trial and $1.0 million upon
the approval of a New Drug Application (“NDA”) for Berubicin; and (v) 200,000 shares of our common stock. The patents we licensed
from HPI expired in March 2020.
On June 10, 2020, the FDA
granted Orphan Drug Designation (“ODD”) for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available
for drugs targeting diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval
of a NDA in the United States. During that period the FDA generally could not approve another product containing the same drug for the
same designated indication. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if
a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product
on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity
is not able to meet market demand. The ODD now constitutes our primary intellectual property protections although the Company is exploring
if there are other patents that could be filed related to Berubicin to extend additional protections.
With the Reata Agreement and
the HPI License, we believe we have obtained all rights and intellectual property necessary to develop Berubicin. As stated earlier, it
is our plan to obtain additional intellectual property covering other compounds which, subject to the receipt of additional financing,
may be developed into drugs for brain and other cancers.
On January 10, 2020, we entered
into a Patent and Technology License Agreement (the “1244 Agreement”) with The Board of Regents of The University of Texas
System, an agency of the State of Texas, on behalf of the UTMDACC. Pursuant to the 1244 Agreement, we obtained a royalty-bearing, worldwide,
exclusive license to certain intellectual property rights, including patent rights, related to our WP1244 drug technology. In consideration,
we must make payments to UTMDACC including an up-front license fee, annual maintenance fee, milestone payments and royalty payments (including
minimum annual royalties) for sales of licensed products developed under the 1244 Agreement. The term of the 1244 Agreement expires on
the last to occur of: (a) the expiration of all patents subject to the 1244 Agreement, or (b) fifteen years after execution; provided
that UTMDACC has the right to terminate the 1244 Agreement in the event that we fail to meet certain commercial diligence milestones.
On May 7, 2020, pursuant to
the WP1244 Portfolio license agreement described above, we entered into a Sponsored Research Agreement with UTMDACC to perform research
relating to novel anticancer agents targeting CNS malignancies. We agreed to fund approximately $1,134,000 over a two-year period. The
principal investigator for this agreement is Dr. Priebe.
Private Placement of Common Shares and Warrants
On January 5, 2022, we entered
into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional investors for the sale of (i) 9,489,474
shares common stock, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,615,790 shares
of common stock, and (iii) warrants to purchase up to an aggregate of 12,105,264 shares of common stock (the “Common Warrants”
and, collectively with the Pre-Funded Warrants, the “Warrants”), in a private placement offering. The combined purchase price
of one share of common stock (or one Pre-Funded Warrant) and accompanying Common Warrant was $0.95.
Subject to certain ownership
limitations, the Warrants are exercisable upon issuance. Each Pre-Funded Warrant is exercisable into one share of common stock at a price
per share of $0.001 (as adjusted from time to time in accordance with the terms thereof). Each Common Warrant is exercisable into one
share of common stock at a price per share of $0.82 (as adjusted from time to time in accordance with the terms thereof) and will expire
on the fifth anniversary of the date of issuance.
In connection with the Purchase
Agreement, we entered in a Registration Rights Agreement and agreed to file by January 20, 2022 a resale registration statement (the “Resale
Registration Statement”) with the SEC covering all shares of common stock sold to investors and the shares of common stock issuable
upon exercise of the Warrants, and to cause the Resale Registration Statement to become effective by March 21, 2022, assuming “full
review” of the Resale Registration Statement by the Commission.
Pursuant to an engagement
letter dated as of January 5, 2022, between us and H.C. Wainwright & Co., LLC (“Wainwright”), we agreed to pay Wainwright
an aggregate fee equal to 7.0% of the gross proceeds received by us from the sale of the securities in the transaction. Pursuant to the
engagement letter, we also issued to Wainwright, or its designees, warrants to purchase up to 5.0% of the aggregate number of shares of
common stock sold in the transactions (the “Placement Agent Warrants”), or 605,263 Placement Agent Warrants. The Placement
Agent Warrants have substantially the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price
equal to 125% of the offering price, or $1.1875 per share, subject to adjustments. We also paid Wainwright $50,000 for non-accountable
expenses and $10,000 for legal fees and expenses.
Corporate Information
Our principal executive office
is located at 2100 West Loop South, Suite 900, Houston, Texas 77027. Our website address is www.cnspharma.com. Information contained in,
or accessible through, our website does not constitute part of this prospectus and inclusions of our website address in this prospectus
are inactive textual references only.
RISK FACTORS
Before making an investment
decision, you should consider the "Risk Factors" included under Item 1A. of our most recent Annual Report on Form 10-K and in
our updates to those Risk Factors in our Quarterly Reports on Form 10-Q, all of which are incorporated by reference in this prospectus,
as updated by our future filings with the SEC. The market or trading price of our common stock could decline due to any of these risks.
In addition, please read "Forward-Looking Statements" in this prospectus, where we describe additional uncertainties associated
with our business and the forward-looking statements included or incorporated by reference in this prospectus. Please note that additional
risks not currently known to us or that we currently deem immaterial may also impair our business and operations.
FORWARD-LOOKING
STATEMENTS
This prospectus and the
documents incorporated herein by reference contain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements are based on our management’s current beliefs, expectations and assumptions about future events,
conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found,
among other places, in the Sections entitled “Business,” “Risk Factors” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” incorporated by reference from our most recent Annual Report on Form 10-K and
in our Quarterly Reports on Form 10-Q, as well as any amendments thereto, filed with the SEC. This prospectus and the documents
incorporated by reference herein also contain estimates and other statistical data made by independent parties and by us relating to market
size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not
to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance
of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
All statements, other
than statements of historical fact, included or incorporated herein regarding our strategy, future operations, financial position, future
revenues, projected costs, plans, prospects and objectives are forward-looking statements. Words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,”
“could,” “will,” “would,” “should,” “continue,” “potential,” “likely,”
“opportunity” and similar expressions or variations of such words are intended to identify forward-looking statements, but
are not the exclusive means of identifying forward-looking statements. These forward-looking statements include, but are not limited to,
statements about:
|
·
|
the economic and market uncertainty caused by the COVID-19 outbreak;
|
|
|
|
|
·
|
our ability to obtain additional funding to develop our product candidates;
|
|
|
|
|
·
|
the need to obtain regulatory approval of our product candidates;
|
|
|
|
|
·
|
the success of our clinical trials through all phases of clinical development;
|
|
|
|
|
·
|
compliance with obligations under intellectual property licenses with third parties;
|
|
|
|
|
·
|
any delays in regulatory review and approval of product candidates in clinical development;
|
|
|
|
|
·
|
our ability to commercialize our product candidates;
|
|
|
|
|
·
|
market acceptance of our product candidates;
|
|
|
|
|
·
|
competition from existing products or new products that may emerge;
|
|
|
|
|
·
|
potential product liability claims;
|
|
|
|
|
·
|
our dependency on third-party manufacturers to supply or manufacture our products;
|
|
|
|
|
·
|
our ability to establish or maintain collaborations, licensing or other arrangements;
|
|
|
|
|
·
|
our ability and third parties’ abilities to protect intellectual property rights;
|
|
|
|
|
·
|
our ability to adequately support future growth; and
|
|
|
|
|
·
|
our ability to attract and retain key personnel to manage our business effectively.
|
Such statements are based
on currently available operating, financial and competitive information and are subject to various risks, uncertainties and assumptions
that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number
of factors including, but not limited to, those set forth above under the section entitled “Risk Factors” in this prospectus
and any accompanying prospectus supplement. Given these risks, uncertainties and other factors, many of which are beyond our control,
you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update
these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after
the date of this prospectus, even if new information becomes available in the future.
USE OF PROCEEDS
All shares
of our common stock offered by this prospectus are being registered for the accounts of the Selling Stockholders, and we will not receive
any proceeds from the sale of these shares. However, we will receive proceeds from the exercise of the warrants, if such warrants are
exercised for cash. We intend to use those proceeds, if any, for general corporate purposes.
SELLING STOCKHOLDERS
The common stock being
offered by the Selling Stockholders are those previously issued to the Selling Stockholders, and those issuable to the Selling Stockholders
upon exercise of the Warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Prospectus Summary – Private Placement of Common Shares and Warrants” above. We are registering the shares of common stock in order to
permit the Selling Stockholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock
and the Warrants, the Selling Shareholders have not had any material relationship with us within the past three years other than as a
result of the ownership of our shares or other securities; provided, however, each of Michael Vasinkevich, Noam Rubinstein,
Michael Mirsky, Craig Schwabe and Charles Worthman are associated persons of Wainwright, which served as our placement agent for the private
placement offering.
The table below lists
the Selling Stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the Selling
Shareholders. The second column lists the number of shares of common stock beneficially owned by each Selling Shareholder, based on its
ownership of the shares of common stock and Warrants, as of January 10, 2022, assuming exercise of the Warrants held by the selling shareholders
on that date, without regard to any limitations on exercises.
The third column lists
the shares of common stock being offered by this prospectus by the Selling Shareholders.
In accordance with the
terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i)
the number of shares of common stock issued to the Selling Shareholders in the “Private Placement of Common Shares and Warrants”
described above and (ii) the maximum number of shares of common stock issuable upon exercise of the related Warrants, determined as if
the outstanding Warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially
filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment
as provided in the registration right agreement, without regard to any limitations on the exercise of the Warrants. The fourth column
assumes the sale of all of the shares offered by the Selling Shareholders pursuant to this prospectus.
Under the terms of the
warrants, a Selling Shareholders may not exercise the Warrants to the extent such exercise would cause such Selling Shareholders, together
with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%,
as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common
stock issuable upon exercise of such Warrants which have not been exercised. The number of shares in the second and fourth columns do
not reflect this limitation. The selling shareholders may sell all, some or none of their shares in this offering. See "Plan of Distribution."
Name of Selling Shareholder
|
|
Number of
Shares
Beneficially
Owned Prior
to this
Offering
|
|
Maximum
Number of
Shares to
be Sold
Pursuant
in this
Offering
|
|
Number of
Shares
Beneficially
Owned
After
Offering *
|
Armistice Capital Master Fund Ltd. (1)
|
|
|
12,631,580
|
|
|
|
12,631,580
|
|
|
|
–
|
|
Cavalry Fund I LP(2)
|
|
|
1,107,632
|
|
|
|
1,052,632
|
|
|
|
55,000
|
|
Cavalry Special Ops Fund LLC (3)
|
|
|
1,107,632
|
|
|
|
1,052,632
|
|
|
|
55,000
|
|
Empery Asset Master, LTD (4)
|
|
|
1,253,250
|
|
|
|
1,253,250
|
|
|
|
–
|
|
Empery Tax Efficient, LP (5)
|
|
|
460,840
|
|
|
|
460,840
|
|
|
|
–
|
|
Empery Tax Efficient III, LP (6)
|
|
|
391,174
|
|
|
|
391,174
|
|
|
|
–
|
|
Hudson Bay Master Fund Ltd. (7)
|
|
|
2,105,264
|
|
|
|
2,105,264
|
|
|
|
–
|
|
Iroquois Capital Investment Group LLC (8)
|
|
|
221,052
|
|
|
|
221,052
|
|
|
|
–
|
|
Iroquois Master Fund Ltd (9)
|
|
|
515,788
|
|
|
|
515,788
|
|
|
|
–
|
|
Intracoastal Capital LLC (10)
|
|
|
2,180,264
|
|
|
|
2,105,264
|
|
|
|
75,000
|
|
Lind Global Fund II LP (11)
|
|
|
1,210,526
|
|
|
|
1,210,526
|
|
|
|
|
|
Lind Global Macro Fund LP (12)
|
|
|
1,460,526
|
|
|
|
1,210,526
|
|
|
|
250,000
|
|
Michael Vasinkevich (13)
|
|
|
388,125
|
|
|
|
388,125
|
|
|
|
–
|
|
Noam Rubinstein (13)
|
|
|
75,658
|
|
|
|
75,658
|
|
|
|
–
|
|
Craig Schwabe (13)
|
|
|
20,428
|
|
|
|
20,428
|
|
|
|
–
|
|
Charles Worthman (13)
|
|
|
6,052
|
|
|
|
6,052
|
|
|
|
–
|
|
Michael Mirsky (13)
|
|
|
115,000
|
|
|
|
115,000
|
|
|
|
–
|
|
*
|
After the offering, none of the Selling Shareholders will have beneficial ownership of greater than one percent of our common stock.
|
(1)
|
The shares are directly held by Armistice Capital
Master Fund Ltd., a Cayman Islands exempted company (the “Master Fund”), and may be deemed to be indirectly beneficially owned
by: (i) Armistice Capital, LLC (“Armistice Capital”), as the investment manager of the Master Fund; and (ii) Steven
Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the securities except
to the extent of their respective pecuniary interests therein.
The number of shares beneficially owned prior
to this offering includes: (i) 2,615,790 shares of common stock issuable upon exercise of the Pre-Funded Warrants held by the Master Fund,
which are subject to beneficial ownership limitations that prohibit the Master Fund from exercising any portion of a warrant if such exercise
would result in the Master Fund owning a percentage of our outstanding common stock exceeding the 9.99% ownership limitation after giving
effect to the issuance of common stock in connection with the Master Fund’s exercise of the Pre-Funded warrant; (ii) 6,315,790 shares
of common stock issuable upon the exercise of Common Warrants, which are subject to beneficial ownership limitations that prohibit the
Master Fund from exercising any portion of a warrant if such exercise would result in the Master Fund owning a percentage of our outstanding
common stock exceeding the 4.99% ownership limitation after giving effect to the issuance of common stock in connection with the Master
Fund’s exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise of all warrants held
by the Master Fund, notwithstanding the existence of beneficial ownership limitations described above.
|
(2)
|
Cavalry Fund I Management LLC is the general partner
of Cavalry Fund I LP and Cavalry Special Ops Fund LLC. As such, Cavalry Fund I Management LLC may be deemed to beneficially own (as that
term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the shares of common stock set forth in the table held by Cavalry
Fund I LP and Cavalry Special Ops Fund LLC. Thomas Walsh is the Manager of Cavalry Fund I Management LLC. Each of Mr. Walsh, Calvary Fund
I LP and Cavalry Special Ops Fund LLC disclaim beneficial ownership of these securities..
The number of shares beneficially owned prior
to this offering for Cavalry Fund I LP includes 526,316 shares of common stock issuable upon exercise of Common Warrants, which are subject
to beneficial ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would result in
the holder owning a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect to the issuance
of common stock in connection with the holder’s exercise of the Common Warrants. The percentage of shares owned after offering assumes
the exercise of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations described above.
|
(3)
|
Cavalry Fund I Management LLC is the general partner
of Cavalry Fund I LP and Cavalry Special Ops Fund LLC. As such, Cavalry Fund I Management LLC may be deemed to beneficially own (as that
term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the shares of common stock set forth in the table held by Cavalry
Fund I LP and Cavalry Special Ops Fund LLC. Thomas Walsh is the Manager of Cavalry Fund I Management LLC. Each of Mr. Walsh, Calvary Fund
I LP and Cavalry Special Ops Fund LLC disclaim beneficial ownership of these securities.
The number of shares beneficially owned prior
to this offering for Cavalry Special Ops Fund LLC includes 526,316 shares of common stock issuable upon exercise of Common Warrants, which
are subject to beneficial ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would
result in the holder owning a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect
to the issuance of common stock in connection with the holder’s exercise of the Common Warrants. The percentage of shares owned
after offering assumes the exercise of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations
described above.
|
(4)
|
Empery Asset Management LP, the authorized agent
of Empery Asset Master Ltd ("EAM"), has discretionary authority to vote and dispose of the shares held by EAM and may be deemed
to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management
LP, may also be deemed to have investment discretion and voting power over the shares held by EAM. EAM, Mr. Hoe and Mr. Lane each disclaim
any beneficial ownership of these shares.
The number of shares beneficially owned prior
to this offering for EAM includes 626,625 shares of common stock issuable upon exercise of Common Warrants, which are subject to beneficial
ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would result in the holder owning
a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect to the issuance of common stock
in connection with the holder’s exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise
of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations described above.
|
(5)
|
Empery Asset Management LP, the authorized agent
of Empery Tax Efficient, LP ("ETE"), has discretionary authority to vote and dispose of the shares held by ETE and may be deemed
to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management
LP, may also be deemed to have investment discretion and voting power over the shares held by ETE. ETE, Mr. Hoe and Mr. Lane each disclaim
any beneficial ownership of these shares.
The number of shares beneficially owned prior
to this offering for ETE includes 230,420 shares of common stock issuable upon exercise of Common Warrants, which are subject to beneficial
ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would result in the holder owning
a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect to the issuance of common stock
in connection with the holder’s exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise
of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations described above.
|
(6)
|
Empery Asset Management LP, the authorized agent
of Empery Tax Efficient III, LP ("ETE III"), has discretionary authority to vote and dispose of the shares held by ETE III and
may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery
Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by ETE III. ETE III, Mr. Hoe
and Mr. Lane each disclaim any beneficial ownership of these shares.
The number of shares beneficially owned prior
to this offering for ETE II includes 195,587 shares of common stock issuable upon exercise of Common Warrants, which are subject to beneficial
ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would result in the holder owning
a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect to the issuance of common stock
in connection with the holder’s exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise
of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations described above.
|
(7)
|
Hudson Bay Capital Management LP, the investment
manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of
Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander
Gerber disclaims beneficial ownership over these securities.
The number of shares beneficially owned prior
to this offering includes 1,052,632 shares of common stock issuable upon exercise of Common Warrants, which are subject to beneficial
ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would result in the holder owning
a percentage of our outstanding common stock exceeding the 9.99% ownership limitation after giving effect to the issuance of common stock
in connection with the holder’s exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise
of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations described above.
|
(8)
|
Richard Abbe is the managing member of Iroquois Capital Investment
Group LLC. Mr. Abbe has voting control and investment discretion over securities held by Iroquois Capital Investment Group LLC. As such,
Mr. Abbe may be deemed to be the beneficial owner (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended)
of the securities held by Iroquois Capital Investment Group LLC.
The number of shares beneficially owned prior to this offering includes
110,526 shares of common stock issuable upon exercise of Common Warrants, which are subject to beneficial ownership limitations that prohibit
the holder from exercising any portion of a warrant if such exercise would result in the holder owning a percentage of our outstanding
common stock exceeding the 4.99% ownership limitation after giving effect to the issuance of common stock in connection with the holder’s
exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise of all warrants held by the holder,
notwithstanding the existence of beneficial ownership limitations described above.
|
(9)
|
Iroquois Capital Management L.L.C. is the investment manager of Iroquois
Master Fund, Ltd. Iroquois Capital Management, LLC has voting control and investment discretion over securities held by Iroquois Master
Fund. As Managing Members of Iroquois Capital Management, LLC , Richard Abbe and Kimberly Page make voting and investment decisions on
behalf of Iroquois Capital Management, LLC in its capacity as investment manager to Iroquois Master Fund Ltd. As a result of the foregoing,
Mr. Abbe and Mrs. Page may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of
1934, as amended) of the securities held by Iroquois Capital Management and Iroquois Master Fund.
The number of shares beneficially owned prior to this offering includes
257,894 shares of common stock issuable upon exercise of Common Warrants, which are subject to beneficial ownership limitations that prohibit
the holder from exercising any portion of a warrant if such exercise would result in the holder owning a percentage of our outstanding
common stock exceeding the 4.99% ownership limitation after giving effect to the issuance of common stock in connection with the holder’s
exercise of the Common Warrants. The percentage of shares owned after offering assumes the exercise of all warrants held by the holder,
notwithstanding the existence of beneficial ownership limitations described above.
|
(10)
|
Mitchell P. Kopin (“Mr. Kopin”) and
Daniel B. Asher (“Mr. Asher”), each of whom are managers of Intracoastal Capital LLC (“Intracoastal”), have shared
voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr. Kopin
and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”)) of the securities reported herein that are held by Intracoastal.
The number of shares beneficially owned prior
to this offering includes: (i) 1,052,632 shares of common stock issuable upon exercise of Common Warrants, and (ii) 75,000 shares of common
stock issuable upon exercise of warrants at an exercise price of $2.20 per share issued in December 2020. The foregoing warrants are subject
to beneficial ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would result in
the holder owning a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect to the issuance
of common stock in connection with the holder’s exercise of such warrants. The percentage of shares owned after offering assumes
the exercise of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations described above.
|
(11)
|
Jeff Easton has voting control and investment
discretion over the securities reported herein that are held by Lind Global Fund II LP and Lind Global Macro Fund LP. Mr. Easton disclaims beneficial ownership over the securities listed except to the extent of his pecuniary interest
therein. The principal business address of Lind is 444 Madison Ave, 41st Floor, New York, NY 10022.
The number of shares beneficially owned prior
to this offering for Lind Global Fund II LP includes 605,263 shares of common stock issuable upon exercise of Common Warrants, which are
subject to beneficial ownership limitations that prohibit the holder from exercising any portion of a warrant if such exercise would result
in the holder owning a percentage of our outstanding common stock exceeding the 4.99% ownership limitation after giving effect to the
issuance of common stock in connection with the holder’s exercise of the Common Warrants. The percentage of shares owned after offering
assumes the exercise of all warrants held by the holder, notwithstanding the existence of beneficial ownership limitations described above.
|
(12)
|
Jeff Easton has voting control and investment
discretion over the securities reported herein that are held by Lind Global Fund II LP and Lind Global Macro Fund LP. Mr. Easton disclaims beneficial ownership over the securities listed except to the extent of his pecuniary interest
therein. The principal business address of Lind is 444 Madison Ave, 41st Floor, New York, NY 10022.
The number of shares beneficially owned prior
to this offering for Lind Global Macro Fund LP includes: (i) 605,263 shares of common stock issuable upon exercise of Common Warrants
and (ii) 250,000 shares of common stock issuable upon exercise of warrants at an exercise price of $2.20 per share issued in December
2020. The foregoing warrants are subject to beneficial ownership limitations that prohibit the holder from exercising any portion of a
warrant if such exercise would result in the holder owning a percentage of our outstanding common stock exceeding the 4.99% ownership
limitation after giving effect to the issuance of common stock in connection with the holder’s exercise of such warrants. The percentage
of shares owned after offering assumes the exercise of all warrants held by the holder, notwithstanding the existence of beneficial ownership
limitations described above.
|
(13)
|
Each of the Selling Stockholders is affiliated with Wainwright, a registered broker dealer and has a registered address of c/o H.C. Wainwright & Co. 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole voting and dispositive power over the securities held. The number of shares beneficially owned prior to this offering consist of shares of common stock issuable upon exercise of Placement Agent Warrants, which were received as compensation for our January 2022 private placement. The Selling Stockholder purchased the Placement Agent Warrants in the ordinary course of business and, at the time the Placement Agent Warrants were acquired, the Selling Stockholder had no agreement or understanding, directly or indirectly, with any person to distribute such securities.
|
PLAN OF DISTRIBUTION
Each Selling Stockholder
of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of
their securities covered hereby on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities
are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more
of the following methods when selling securities:
|
·
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
|
|
|
·
|
block trades in which the broker-dealer will attempt to sell the securities as agent but may position
and resell a portion of the block as principal to facilitate the transaction;
|
|
|
|
|
·
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
|
|
|
·
|
an exchange distribution in accordance with the rules of the applicable exchange;
|
|
|
|
|
·
|
privately negotiated transactions;
|
|
|
|
|
·
|
settlement of short sales;
|
|
|
|
|
·
|
in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number
of such securities at a stipulated price per security;
|
|
|
|
|
·
|
through the writing or settlement of options or other hedging transactions, whether through an options
exchange or otherwise;
|
|
|
|
|
·
|
a combination of any such methods of sale; or
|
|
|
|
|
·
|
any other method permitted pursuant to applicable law.
|
The Selling Stockholders
may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.
Broker-dealers engaged
by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in
compliance with FINRA 2121.
In connection with the
sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume.
The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge
the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other
transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery
to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or
other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The Selling Stockholders
and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the
meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.
The Company is required
to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify
the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
We agreed to keep this
prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without
registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other
rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied
with.
Under applicable rules
and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage
in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to
the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act
and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock
by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have
informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act).
WHERE
YOU CAN FIND MORE INFORMATION
We have filed with the SEC
a registration statement on Form S-3 under the Securities Act with respect to the securities offered in this offering. We file annual,
quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. You may read and copy
the registration statement and any other documents we have filed at the Securities and Exchange Commission’s Public Reference Room
100 F Street, N.E., Washington, D.C. 20549. Please call the Securities and Exchange Commission at 1-800-SEC-0330 for further information
on the Public Reference Room. Our Securities and Exchange Commission filings are also available to the public at the Securities and Exchange
Commission’s Internet site at www.sec.gov.
This prospectus is part of
the registration statement and does not contain all of the information included in the registration statement. Whenever a reference is
made in this prospectus to any of our contracts or other documents, the reference may not be complete and, for a copy of the contract
or document, you should refer to the exhibits that are a part of the registration statement.
INCORPORATION
BY REFERENCE
The SEC allows us to "incorporate
by reference" into this prospectus the information we file with it, which means that we can disclose important information to you
by referring you to those documents. Later information filed with the SEC will update and supersede this information.
We incorporate by reference
the documents listed below, all filings filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date
of the initial registration statement of which this prospectus forms a part prior to effectiveness of such registration statement, and
any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the time that all securities
covered by this prospectus have been sold or the offering is otherwise terminated; provided, however, that we are not incorporating any
information furnished under either Item 2.02 or Item 7.01 of any current report on Form 8-K:
• Our Annual Report on Form 10-K for the
year ended December 31, 2020 filed on February 12, 2021 (as amended on February 16, 2021 and April 30, 2021);
• Our Quarterly Reports on Form 10-Q for
the fiscal quarters ended March 31, 2021 (filed on May 13, 2021), June 30, 2021 (filed on August 13, 2021), and September 30, 2021 (filed
on November 12, 2021);
• Our Current Reports on Form 8-K filed
on February 12, 2021; July 1, 2021; and January 6, 2022;
• Our Definitive Proxy Statement on Schedule
14A filed on June 8, 2021; and
• the description of our common stock,
par value $0.001 per share contained in our Registration Statement on Form 8-A, dated and filed with the SEC on November 5, 2019, and
any amendment or report filed with the SEC for the purpose of updating the description.
We will provide to each person, including any
beneficial owner, to whom this prospectus is delivered, upon written or oral request, at no cost to the requester, a copy of any and all
of the information that is incorporated by reference in this prospectus. You may request a copy of these filings, at no cost, by contacting
us at:
CNS Pharmaceuticals, Inc.
Attn: Corporate Secretary
2100 West Loop South, Suite 900
Houston, TX 77027
Phone: (800) 946-9185
LEGAL MATTERS
Schiff Hardin
LLP, Washington, D.C., will pass for us upon the validity of the securities being offered by this prospectus.
EXPERTS
The financial statements as of and for the years ended December 31, 2020 and 2019, included in our Annual Report on Form 10-K for
the year ended December 31, 2020, have been audited by MaloneBailey, LLP, independent registered public accounting firm, as set forth
in their report, and have been incorporated herein by reference in reliance on the report of MaloneBailey, LLP, given on the authority
of such firm as experts in auditing and accounting.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance
and Distribution
The
following table sets forth the estimated costs and expenses to be incurred in connection with the issuance and distribution of the securities
of CNS Pharmaceuticals, Inc., which are registered under this Registration Statement on Form S-3, other than underwriting discounts and
commissions. All amounts are estimates except the Securities and Exchange Commission registration fee.
SEC registration fee
|
|
$
|
1,702
|
|
Legal fees and expenses
|
|
$
|
10,000
|
|
Accounting fees and expenses
|
|
$
|
5,000
|
|
Printing and miscellaneous expenses
|
|
$
|
5,000
|
|
Total
|
|
$
|
21,702
|
|
Item 15. Indemnification of Officers
and Directors
Section 78.138 of the Nevada Revised Statute provides
that a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result
of any act or failure to act in his capacity as a director or officer unless it is proven that (1) his act or failure to act constituted
a breach of his fiduciary duties as a director or officer and (2) his breach of those duties involved intentional misconduct, fraud or
a knowing violation of law.
This provision is intended to afford directors
and officers protection against and to limit their potential liability for monetary damages resulting from suits alleging a breach of
the duty of care by a director or officer. As a consequence of this provision, stockholders of our company will be unable to recover monetary
damages against directors or officers for action taken by them that may constitute negligence or gross negligence in performance of their
duties unless such conduct falls within one of the foregoing exceptions. The provision, however, does not alter the applicable standards
governing a director’s or officer’s fiduciary duty and does not eliminate or limit the right of our company or any stockholder
to obtain an injunction or any other type of non-monetary relief in the event of a breach of fiduciary duty.
The Registrant’s Articles of Incorporation,
as amended, and amended and restated bylaws provide for indemnification of directors, officers, employees or agents of the Registrant
to the fullest extent permitted by Nevada law (as amended from time to time). Section 78.7502 of the Nevada Revised Statute provides that
such indemnification may only be provided if the person acted in good faith and in a manner he or she reasonably believed to be in, or
not opposed to, the best interest of the Registrant and, with respect to any criminal action or proceeding, had no reasonable cause to
behave his conduct was unlawful. We have purchased and intend to maintain insurance on behalf of any person who is or was a director or
officer of our company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity,
subject to certain exclusions. The foregoing may reduce the likelihood of derivative litigation against our directors and executive officers
and may discourage or deter stockholders or management from suing directors or executive officers for breaches of their duty of care,
even though such actions, if successful, might otherwise benefit the company and our stockholders.
Item 16. Exhibits
Item 17. Undertakings
The undersigned registrant
hereby undertakes:
1) To file, during any
period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the “Commission”), pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii)
to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement;
Provided, however,
that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the registration statement is on Form S-3 or Form F-3 and
the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished
to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (the “Exchange
Act”), that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant
to Rule 424(b) that is part of the registration statement.
2) That, for the purpose
of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
3) To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
4) That, for the purpose
of determining liability under the Securities Act to any purchaser:
i.
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and
ii.
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule
430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required
by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier
of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering
described in prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement
to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. Provided, however , that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in
any such document immediately prior to such effective date.
5) That, for purposes
of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to section 13(a) or
section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section
15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
6) Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned
thereunto duly authorized, in the City of Houston, State of Texas, on January 20, 2022.
|
CNS PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/S/ John Climaco
|
|
Name:
|
John Climaco
|
|
Title:
|
Chief Executive Officer and Director
|
KNOW ALL MEN AND WOMEN BY THESE
PRESENTS, that each person whose signature appears below constitutes and appoints either John Climaco or Christopher Downs, his true and
lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him and in his name, place and stead, in any
and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and any subsequent
registration statements pursuant to Rule 462 of the Securities Act of 1933 and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each
of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact
or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates
indicated:
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ John Climaco
|
|
Chief Executive Officer and Director
|
|
January 20, 2022
|
John Climaco
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Christopher Downs
|
|
Chief Financial Officer
|
|
January 20, 2022
|
Christopher Downs
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Jerzy Gumulka
|
|
Director
|
|
January 20, 2022
|
Jerzy (George) Gumulka
|
|
|
|
|
|
|
|
|
|
/s/ Carl Evans
|
|
Director
|
|
January 20, 2022
|
Carl Evans
|
|
|
|
|
|
|
|
|
|
/s/ Jeffrey Keyes
|
|
Director
|
|
January 20, 2022
|
Jeffrey Keyes
|
|
|
|
|
|
|
|
|
|
/s/ Andrzej Andraczke
|
|
Director
|
|
January 20, 2022
|
Andrzej Andraczke
|
|
|
|
|
|
|
|
|
|
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Feb 2024 to Mar 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Mar 2023 to Mar 2024